[Skip to Content]
Wirral University Hospital NHS Foundation Trust

Lungs

This is a list of conditions we currently have research studies for. Click to reveal more.

Pneumonia

What is the study about?

Pneumonia is an inflammation of one or both lungs, usually caused by infection. Around 1 in 20 patients (5%) who are admitted to hospital with pneumonia have a heart attack or stroke within three months.

Aspirin has been used for decades to reduce the chance of having a heart attack or stroke in other patient groups. Although aspirin has limited side effects in the vast majority of people, it carries a very small risk of significant bleeding, therefore it is not clear whether or not giving aspirin to everyone with pneumonia will be beneficial overall.

The ASPECT trial aims to test whether aspirin reduces the risk of a heart attack or stroke in patients who are admitted to hospital with pneumonia. This study needs to recruit 22,600 patients over 4-years to answer this question.

Adults aged 50 years and over admitted to hospital with pneumonia will be invited to take part. Those who agree will be split into two groups. One group will be asked to take a course of low dose aspirin each day for 3 months. The other group will not.

 

Who can take part?

Patients who are admitted to hospital with a lung infection known as pneumonia.

 

What is involved?

You will be given either aspirin daily or no aspirin, which is chosen at random. No further hospital visits are required and you continue your aspirin at home. Taking part does not increase your hospital stay.

 

How do I take part

Patients who are eligible with be approached to take part. Ask your doctor whilst you are in hospital.

Collapsed Lung

What is this study about?

We are recruiting patients who are admitted to hospital with a collapsed lung (pneumothorax). Patients often require treatment to re-inflate the lung. The trial is looking at whether low-grade suction applied to the chest tube, vs. no suction (which we call standard care), re-inflates the lung quicker. The trial is called RASPER, which stands for RANDOMISED TRIAL OF SUCTION FOR PRIMARY PNEUMOTHORAX EARLY RESOLUTION.

It's hoped that applying suction will reduce length of stay in hospital and complications. Benefits include potential re-inflation more quickly in the suction group, but we do not know this for sure.

Who can take part?

Patients who are admitted to the hospital with air in the lung wall, a condition known as pneumothorax.

 

What's involved?

Your treatment will continue as normal, but you may be given a drain with or without suction; you will be told which treatment you are given. Every day, whilst you are in hospital, you will get an email with a link to a questionnaire with 2 questions about your pain. When you are discharged from hospital you will be followed up via a telephone by our research team. This study does not delay your discharge and there are no further visits to hospital.

 

How do I take part?

The study is run by the pleural team at Arrowe Park Hospital ward 38.

You will be approached by your pleural team, doctor or research nurse if you are eligible. 

Bronchiectasis with Pseudomonas Infection

ESCAPE logo

 

What is the trial about?

Bronchiectasis is a long-term lung condition that can cause a persistent cough and repeated chest infections. Some people with bronchiectasis develop an infection caused by a type of bacteria called Pseudomonas, which can be difficult to treat and may become a long-term infection.

The ESCAPE trial is looking at whether treating a new Pseudomonas infection with antibiotics, followed by three months of inhaled antibiotics delivered through a nebuliser, can clear the infection and improve symptoms. The results will help researchers identify the best treatment approach for people with bronchiectasis who develop a new Pseudomonas infection.

Who can take part?

You may be able to take part if:

  • You have been diagnosed with bronchiectasis
  • A recent sputum sample has shown a new Pseudomonas infection
  • Your healthcare team believes the trial may be suitable for you

A member of the research team will discuss the full eligibility criteria with you.

 

What is involved?

Taking part in the trial is entirely voluntary. If you choose to take part, you will:

  • Attend approximately 4-5 hospital visits over a two-year period
  • Be allocated by chance (randomised) to either the trial treatment group or the usual care group
  • Receive regular health checks from the research team
  • Provide sputum samples during trial visits
  • Complete questionnaires about your health and symptoms
  • Keep a brief daily symptom diary throughout the trial
  • Receive ongoing support from the research team

Trial treatment group

  • Antibiotic treatment (tablets or intravenous antibiotics, depending on your clinical needs).
  • A three-month course of inhaled antibiotics delivered through a nebuliser.

Usual care group

  • Usual treatment provided by your doctor
  • This may include a short course of antibiotics if you develop symptoms of infection

Taxi transport may be arranged, or reasonable travel expenses may be reimbursed.

Tell me more

For further information about the ESCAPE trial, please visit:

ESCAPE Trial Information

 

How do I take part?

If you would like more information or are interested in taking part, please contact:

Deborah Whyte, Research Nurse
Email: deborahwhyte@nhs.net

or

Research Department
Email: wih-tr.ResearchDepartment@nhs.net

A member of the research team will be happy to discuss the trial with you and answer any questions.